Please login to the form below

Not currently logged in
Email:
Password:

Ariad appoints new CEO

Paris Panayiotopoulos joins the US biotech from EMD Serono

Ariad Paris PanayiotopoulosParis Panayiotopoulos has moved from EMD Serono to join Ariad as its new president and CEO.

Panayiotopoulos succeeds Ariad's founder, chairman and CEO Harvey Berger who is retiring from the Cambridge, US-based biotech company he set up 23 years ago.

Berger will continue at Ariad for a time, serving as a special advisor to its board and new CEO Panayiotopoulos as part of the transition process.

Wayne Wilson, lead director for Ariad, said: “Paris is a dynamic leader with a proven ability to set vision, define strategy, build culture and align teams to successfully execute against objectives.

“He has the necessary skills to bring a renewed focus to company execution as we work together to explore all paths in maximising value for shareholders.”

Prior to his time at EMD Serono, where he was its president, and its parent company Merck KGaA Panayiotopoulos was at Lilly.

Panayiotopoulos said: “I am very pleased to be joining ARIAD at this exciting time. Together with our passionate and highly capable employees, I fully expect that we will maximise the company's commercial potential and further strengthen its pipeline.”

5th January 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics